Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: Randomized phase III trial (E2995).

被引：0
|
作者：
Greenberg, P
Advani, R
Tallman, M
Letendre, L
Saba, H
Dugan, K
Lee, SJ
Lum, B
Sikic, BI
Paietta, E
Bennett, J
Rowe, JM
机构：
[1] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[2] Northwestern Univ, Med Ctr, Chicago, IL 60611 USA
[3] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA
[4] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[5] Montefiore Med Ctr, Bronx, NY 10467 USA
[6] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1703
引用
收藏
页码：383A / 383A
页数：1
相关论文
共 22 条
  • [1] Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC)
    Advani, R
    Saba, H
    Rowe, JM
    Tallman, M
    Wiernik, P
    Ramek, J
    Dugan, K
    Litchman, M
    Dorr, R
    Lum, B
    Sikic, B
    Davis, E
    Paietta, E
    Greenberg, P
    BLOOD, 1996, 88 (10) : 847 - 847
  • [2] Treatment of poor prognosis AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC).
    Advani, R
    Saba, HI
    Tallman, M
    Rowe, JM
    Wiernik, PH
    Ramek, J
    Dugan, K
    Lum, B
    Villena, J
    Sikic, BI
    Davis, E
    Paietta, E
    Litchman, M
    Greenberg, P
    BLOOD, 1997, 90 (10) : 2260 - 2260
  • [3] Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC)
    Advani, R
    Visani, G
    Milligan, D
    Saba, H
    Tallman, M
    Rowe, JM
    Wiernik, PH
    Ramek, J
    Dugan, K
    Lum, B
    Villena, J
    Davis, E
    Paietta, E
    Litchman, M
    Covelli, A
    Sikic, B
    Greenberg, P
    DRUG RESISTANCE IN LEUKEMIA AND LYMPHOMA III, 1999, 457 : 47 - 56
  • [4] A phase I dose-finding study of PSC 833, a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine (PSC-MEC) in poor prognosis acute leukemia (AML).
    Visani, G
    Milligan, D
    Leoni, F
    Chang, J
    Kelsey, S
    Marcus, R
    Powles, R
    Schey, S
    Covelli, A
    BLOOD, 1997, 90 (10) : 2518 - 2518
  • [5] Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995)
    Greenberg, PL
    Lee, SJ
    Advani, R
    Tallman, MS
    Sikic, BI
    Letendre, L
    Dugan, K
    Lum, B
    Chin, DL
    Dewald, G
    Paietta, E
    Bennett, JM
    Rowe, JM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) : 1078 - 1086
  • [6] A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Bortezomib for Relapsed/Refractory Acute Myeloid Leukemia
    Advani, Anjali
    Elson, Paul
    Hsi, Eric D.
    Davis, Randall
    Kalaycio, Matt
    Sobecks, Ronald
    Copelan, Edward
    Duong, Hien K.
    Foster, Bethany
    Rush, Mary Lynn
    Farhat, Leslie
    Sekeres, Mikkael A.
    BLOOD, 2012, 120 (21)
  • [7] Bortezomib plus MEC (Mitoxantrone, Etoposide, Cytarabine) for Relapsed/Refractory Acute Myeloid Leukemia: Final Results of an Expanded Phase 1 Trial
    Advani, Anjali S.
    Elson, Paul
    Kalaycio, Matt E.
    Mukherjee, Sudipto
    Gerds, Aaron T.
    Hamilton, Betty K.
    Hobson, Sean
    Smith, Arian
    Rush, Mary Lynn
    Bogati, Samjhana
    Biggins, Monique
    Hsi, Eric D.
    Duong, Hien K.
    Copelan, Edward A.
    Reu, Frederic J.
    Saunthararajah, Yogen
    Nazha, Aziz
    Makishima, Hideki
    Przychodzen, Bartlomiej
    Dienes, Brittney
    Maciejewski, Jaroslaw P.
    Carew, Jennifer S.
    Carraway, Hetty E.
    Sekeres, Mikkael A.
    BLOOD, 2014, 124 (21)
  • [8] A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Advani, Anjali S.
    Cooper, Brenda
    Elson, Paul
    Mukherjee, Sudipto
    Fensterl, Jaime
    Gerds, Aaron T.
    Caimi, Paolo F.
    Tomlinson, Ben K.
    Malek, Ehsan
    Little, Jane A.
    Rush, Mary Lynn
    Bogati, Samjhana
    Parsons, Eric
    Kane, Donna
    Carraway, Hetty E.
    Nazha, Aziz
    Hamilton, Betty K.
    Sobecks, Ronald
    Bevier, Barbara
    Goebel, Christopher
    Zimmerman, Cassie
    Nielsen, Alek D.
    Hirsch, Cassandra M.
    Maciejewski, Jaroslaw P.
    Kalaycio, Matt
    deLima, Marcos
    Jacobberger, James
    Woost, Philip
    Sekeres, Mikkael A.
    BLOOD, 2016, 128 (22)
  • [9] Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia
    Kornblau, SM
    Estey, E
    Madden, T
    Tron, HT
    Zhao, S
    Consoli, U
    Snell, V
    SanchezWilliams, G
    Kantarjian, H
    Keating, M
    Newman, RA
    Andreeff, M
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) : 1796 - 1802
  • [10] A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML): Final Results
    Advani, Anjali S.
    Cooper, Brenda W.
    Visconte, Valeria
    Elson, Paul
    Chan, E. Ricky
    Carew, Jennifer
    Mukherjee, Sudipto
    Gerds, Aaron T.
    Carraway, Hetty E.
    Nazha, Aziz
    Hamilton, Betty K.
    Sobecks, Ronald
    Caimi, Paolo
    Tomlinson, Benjamin
    Malek, Ehsan
    Little, Jane A.
    Fensterl, Jaime
    Unger, Allison
    Zimmerman, Cassie
    Goebel, Christopher
    Hoxha, Nita
    Siebenaller, Caitlin
    Thomas, Jenna
    Rush, Mary Lynn
    Bogati, Samjhana
    Parsons, Eric
    Diligente, Rachael
    Kane, Donna
    Nielsen, Alek
    Hirsch, Cassandra M.
    Edelheit, Simone
    Miron, Alexander
    Pink, John
    Maciejewski, Jaroslaw P.
    Kalaycio, Matt
    De Lima, Marcos
    Sekeres, Mikkael A.
    BLOOD, 2017, 130
123